文献速递消化道肿瘤放疗

AN0025(一种新型PGE2受体EP4拮抗剂)联合全程新辅助治疗用于局部晚期直肠癌

AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer.
PubMed 文献 · Radiother Oncol · 2023-04-11

这项多中心、开放标签的Ib期试验纳入28例局部晚期直肠癌受试者,接受AN0025每日250 mg或500 mg共10周,联合长程或短程放化疗。未观察到符合剂量限制标准的治疗中出现的不良事件或严重不良事件,9/25例(36.0%)达到病理完全缓解或临床完全缓解;中位随访30个月时,12个月无病生存率为77.5%(95%CI:56.6,89.2),总生存率为96.3%(95%CI:76.5,99.5)。作者认为该方案耐受性良好,显示出诱导病理和临床完全缓解的潜力,值得在更大规模临床试验中进一步研究。

要点

  • 28例局部晚期直肠癌受试者接受AN0025(250 mg或500 mg,每日一次,共10周)联合长程或短程放化疗。
  • 未观察到符合剂量限制标准的治疗中出现的不良事件或严重不良事件,仅3例因不良事件停用AN0025。
  • 25例可评估疗效者中9例(36.0%)达到病理完全缓解或临床完全缓解,其中手术的15例中4例(26.7%)达到病理完全缓解。

核心结论

  • AN0025联合术前短程或长程放化疗治疗10周似乎未加重局部晚期直肠癌受试者的毒性,耐受性良好,并显示出诱导病理完全缓解和临床完全缓解的潜力。
  • 作者认为其活性值得在更大规模临床试验中进一步研究。

研究设计与样本

  • 多中心、开放标签、Ib期试验,纳入28例局部晚期直肠癌受试者。
  • 受试者接受AN0025 250 mg或500 mg每日一次共10周,联合长程或短程放化疗(每组7例)。
  • 从首次给药开始评估安全性和疗效,随访2年。

主要发现

  • 未观察到符合剂量限制标准的治疗中出现的不良事件或严重不良事件,仅3例受试者因不良事件停用AN0025。
  • 28例中25例完成10周AN0025及辅助治疗并纳入疗效评估。
  • 总体9/25例(36.0%)达到病理完全缓解或临床完全缓解,其中接受手术的15例中4例(26.7%)达到病理完全缓解。
  • 65.4%的受试者在治疗完成后磁共振成像证实降期至≤3期。
  • 中位随访30个月,12个月无病生存率为77.5%(95%CI:56.6,89.2),总生存率为96.3%(95%CI:76.5,99.5)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为AN0025联合术前放化疗的活性值得在更大规模临床试验中进一步研究。

局限性

  • 原文结论提出这些发现提示其活性值得在更大规模临床试验中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the safety and efficacy of AN0025 in combination with preoperative radiotherapy and chemotherapy in either short course (SCRT) or long course radiotherapy (LCRT) settings for those with locally advanced rectal cancer. PATIENTS AND METHODS: Twenty-eight subjects with locally advanced rectal cancer participated in this multicenter, open-label, Phase Ib trial. Enrolled subjects received either 250 mg or 500 mg of AN0025 once daily for 10 weeks with either LCRT or SCRT with chemotherapy (7 subjects/group). Participants were assessed for safety/efficacy starting from the first dose of study drug administration and were followed for 2 years. RESULTS: No treatment-emergent adverse or serious adverse events meeting dose-limiting criteria were observed, with only 3 subjects discontinuing AN0025 treatment due to adverse events. Twenty-five of 28 subjects completed 10 weeks of AN0025 and adjuvant therapy and were evaluated for efficacy. Overall, 36.0% of subjects (9/25 subjects) achieved a pathological complete response or a complete clinical response, including 26.7% of subjects (4/15 subjects who underwent surgery) who achieved a pathological complete response. A total of 65.4% of subjects had magnetic resonance imaging-confirmed down-staging ≤ stage 3 following completion of treatment. With a median follow-up of 30 months. The 12-month disease-free survival and overall survival were 77.5% (95% confidence interval [CI]: 56.6, 89.2) and 96.3% (95% CI: 76.5, 99.5), respectively. CONCLUSIONS: Treatment with AN0025 administered for 10 weeks along with preoperative SCRT or LCRT did not appear to worsen the toxicity in subjects with locally advanced rectal cancer, was well-tolerated and showed promise in inducing both a pathological and complete clinical response. These findings suggest its activity deserves further investigation in larger clinical trials.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Wyrwicz L, Saunders M, Hall M, et al. AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023. PMID: 37054987. doi:10.1016/j.radonc.2023.109669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。